MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$613,933
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Research and development
223,564
340,562
757,248
377,789
General and administrative
395,033
355,070
557,866
363,426
Total expenses
618,597
695,632
1,315,114
741,215
Loss from operations
-618,597
-695,632
-1,315,114
-741,215
Interest income
4,664
9,207
19,749
29,031
Net loss
-613,933
-686,425
-1,295,365
-712,184
Basic EPS
0
0
-0.008
0
Diluted EPS
0
0
-0.008
0
Basic Average Shares
173,307,525
172,573,545
172,576,969
172,573,545
Diluted Average Shares
173,307,525
172,573,545
172,576,969
172,573,545
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
-$613,933
(6.97%↑ Y/Y)
Interest income
$4,664
(-86.98%↓ Y/Y)
Loss from operations
-$618,597
(11.09%↑ Y/Y)
Total expenses
$618,597
(-11.09%↓ Y/Y)
General and
administrative
$395,033
(6.72%↑ Y/Y)
Research and development
$223,564
(-31.34%↓ Y/Y)
Buy us a coffee
Inhibitor Therapeutics, Inc. (INTI)
Inhibitor Therapeutics, Inc. (INTI)